Iovance Biotherapeutics (NASDAQ: IOVA)
Iovance Biotherapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Iovance Biotherapeutics Company Info
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
News & Analysis
Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week
Down More Than 75% This Year, Should Investors Throw in the Towel on Iovance Biotherapeutics Stock?
Why Iovance Biotherapeutics Tumbled by Nearly 6% Today
Is This Beaten-Down Stock a Buy Near Its 52-Week Low?
Why Iovance Biotherapeutics Stock Is Crashing Today
2 Beaten-Down Stocks With Incredible Upside Potential
Iovance Biotherapeutics Stock Is Crashing. And Here's Why Things Could Get Even Worse This Year.
This Biotech Stock Could Be the Best Investment of the Decade
There's an incredible growth story hiding in plain sight for investors who can look to the future.
Valuation
Earnings Transcripts
Iovance Biotherapeutics, inc (IOVA) Q3 2021 Earnings Call Transcript
IOVA earnings call for the period ending September 30, 2021.
Iovance Biotherapeutics, Inc. (IOVA) Q1 2020 Earnings Call Transcript
IOVA earnings call for the period ending March 31, 2020.
Iovance Biotherapeutics, Inc. (IOVA) Q4 2019 Earnings Call Transcript
IOVA earnings call for the period ending December 31, 2019.
Iovance Biotherapeutics, Inc. (IOVA) Q3 2019 Earnings Call Transcript
IOVA earnings call for the period ending September 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.